Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

• Status: Completed
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3 fatty acid may help doctors learn more about the effects of omega-3 fatty acid on tumor cells.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Collaborator: National Cancer Institute (NCI)

Criteria

Inclusion Criteria:

• Newly diagnosed stage I to III breast cancer and carcinoma in situ (including lobular carcinoma in situ [LCIS] and ductal carcinoma in situ [DCIS])

• Breast surgery (lumpectomy or mastectomy) is planned for at least 7 days from the day of enrollment

• Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved written informed consent document

• Tumor measures at least 1 centimeter on imaging or physical exam

Exclusion Criteria:

• Any patient with surgery scheduled < 7days after biopsy

• Patients who are unable to refrain from the use of any NSAID or full-dose acetylsalicylic acid (ASA)-containing NSAID while taking study drug

• Patients who will receive neoadjuvant chemotherapy are not eligible

• Patients who are currently taking omega-3 fatty acids, as they are unable to be randomized to placebo

• Patients who have previously taken omega-3 fatty acid within 1 month prior to study enrollment

• Patients with an allergy or known hypersensitivity to fish